HAO1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL255078	0.51	10/20
SCHEMBL236825	0.43	7/20
SCHEMBL233645	0.41	6/20
SCHEMBL292473	0.42	3/20
SCHEMBL260615	0.54	2/20
SCHEMBL570533	0.50	2/20
SCHEMBL42782	0.48	2/20
SCHEMBL689331	0.48	2/20
SCHEMBL492289	0.48	2/20
SCHEMBL363299	0.46	2/20
SCHEMBL402092	0.46	2/20
SCHEMBL527210	0.46	2/20
SCHEMBL61119	0.44	2/20
SCHEMBL271455	0.43	2/20
SCHEMBL719199	0.41	2/20
SCHEMBL487465	0.41	2/20
SCHEMBL81119	0.39	2/20
SCHEMBL718613	0.39	2/20
Dimethylamine (SCHEMBL700542)	0.38	2/20
SCHEMBL233144	0.38	2/20

Clinical trials — most relevant to HAO1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Multiple N-of-1 Trials of (Intermittent) Hypoxia Therapy in Parkinson's Disease	PHASE1/PHASE2	COMPLETED
Use of ACTIMMUNE in Patients With ADO2	PHASE2	COMPLETED
Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder	PHASE2	COMPLETED
First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer	PHASE2	COMPLETED
Long-Term Study of Nitisinone to Treat Alkaptonuria	PHASE2	COMPLETED
Statin Therapy to Improve Medication Adherence	PHASE1	COMPLETED
Prevalence of DAO (diamino Oxidase) Deficiency in Newborns	nan	COMPLETED
Rare Kidney Stone Consortium Biobank	nan	RECRUITING
Predictors of Outcome of Pediatric Renal Transplantation	nan	NOT_YET_RECRUITING
In Vivo Assessment of Histamine Pharmacodynamics	nan	WITHDRAWN
Primary Hyperoxaluria Mutation Genotyping/Phenotyping	nan	COMPLETED
Genetic DAO Deficiency and Lower Urinary Tract Symptoms	nan	COMPLETED
Genetic Determinants of Congenital Heart Disease Outcomes	nan	COMPLETED
Mitochondrial Function of Immune Cells in Sepsis	nan	COMPLETED
Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma	nan	RECRUITING
Replacement of Vitamin D in Patients With Active Tuberculosis	nan	COMPLETED
Vancomycin Associated Red Man Syndrome (RMS)	nan	COMPLETED
International Registry for Primary Hyperoxaluria	nan	WITHDRAWN
Primary Hyperoxaluria Mutation Genotyping	nan	COMPLETED
Markers of Inflammation and Lung Recovery in ECMO Patients for PPHN	nan	COMPLETED
Relationship Between Vascular Endothelial Dysfunction and Beat-to-beat Blood Pressure Variability in Patients With OSAS	nan	UNKNOWN
Effect of ORI-guided Oxygen Titration on Oxidative Stress in Rhinoplasty Surgery	nan	COMPLETED
Effect of Low Histamine-Based Modified Mediterranean Diet in Multiple Sclerosis	nan	COMPLETED
Purine Metabolism Enzyme SNP to Uric Acid Production	nan	COMPLETED
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia	nan	UNKNOWN
Rare Obesity Cohorts With Food Behavioral Disorders : Better Diagnosis for Better Treatment	nan	RECRUITING
Clinical, Cellular, and Molecular Investigation Into Oculocutaneous Albinism	nan	COMPLETED
Mechanistic Studies of Teriflunomide in RRMS	nan	COMPLETED
Study of Protein Translocation in Patients With Beta-Oxidation Disorders	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HAO1 binder may also engage these)

Protein	Name	Similarity
Q9WU19	—	0.999	Q9WU19 →
B0BNF9	—	0.999	B0BNF9 →
Q9LJH5	—	0.998	Q9LJH5 →
Q7XPR4	—	0.997	Q7XPR4 →
B8B8K5	—	0.994	B8B8K5 →
Q9LRR9	—	0.993	Q9LRR9 →
Q7FAS1	—	0.993	Q7FAS1 →
Q01KC2	—	0.993	Q01KC2 →
Q24JJ8	—	0.992	Q24JJ8 →
Q8H3I4	—	0.992	Q8H3I4 →
HAO2	2-Hydroxyacid oxidase 2	0.991	landscape →
Q9NYQ2	—	0.991	Q9NYQ2 →
Q07523	—	0.991	Q07523 →
B8AUI3	—	0.991	B8AUI3 →
Q6YT73	—	0.990	Q6YT73 →
O49506	—	0.990	O49506 →
S0DRI9	—	0.989	S0DRI9 →
P05414	—	0.989	P05414 →
Q3ZBW2	—	0.988	Q3ZBW2 →
Q9LRS0	—	0.988	Q9LRS0 →
B8B7C5	—	0.988	B8B7C5 →
B1HZY7	—	0.987	B1HZY7 →
A0A3L6E0R4	—	0.987	A0A3L6E0R4 →
B8AKX6	—	0.986	B8AKX6 →
A0A1U8QTA2	—	0.986	A0A1U8QTA2 →
Q4QJK8	—	0.986	Q4QJK8 →
A0A0D2YG00	—	0.986	A0A0D2YG00 →
W7NCP1	—	0.985	W7NCP1 →
Q54E41	—	0.985	Q54E41 →
Q10CE4	—	0.985	Q10CE4 →